ANeuroTech
ANeuroTech is developing its late stage Phase III drug ANT01, an once-daily orally-administered small molecule targeting Partial Responsive Depression (PRD) and subjective cognitive decline. ANT01 acts as a combined High Selective Serotonin 2A/Dopamine 4 receptor blocker. The company was founded by Dr. Erik Buntinx, a psychiatrist with over 3 decades of experience in clinical neuroscience drug development.
Key People
Erik Buntinx - Founding CEO and Chief Scientific Officer